RxDoctor Payments Data

Paul Berkowitz, MD

Psychiatry · Libertyville, ILNPI 1275564197

Payments from drug & device makers

$2,263in general payments, 2019–2025

Across 55 payments — averaging $41.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$1K
  • Johnson & Johnson$482
  • Otsuka America Pharmaceutical, Inc.$125
  • Axsome Therapeutics, Inc.$95
  • AbbVie$83
  • Lundbeck LLC$57
  • plus $340 from 12 others

What the payments were for

  • Speaking & faculty fees$1,06947%
  • Food & beverage$1,19453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,263 in reported general payments places this provider in the 80th percentile of 1,344 psychiatry providers in Illinois.

See all psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$98,104
Medicare patients
68
Services billed
999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl20$25,736
CaplytaLumateperone Tosylate11$18,627
ParnateTranylcypromine Sulfate12$17,518
Quetiapine Fumarate88$2,760
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine39$1,374
Escitalopram Oxalate75$1,330
Aripiprazole39$1,229
Dextroamphetamine Sulfate ErDextroamphetamine Sulfate12$1,165
Duloxetine Hcl62$1,083
Bupropion XlBupropion Hcl43$1,024
Clonazepam98$847
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine14$700
Oxcarbazepine19$679
Lamotrigine49$537
Olanzapine30$470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$482$25,73620 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$56$18,62711 claims
Almatica Pharma LLCSertraline Hcl$20$38547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,344 psychiatry providers in Illinois.

Other psychiatry in Libertyville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →